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Victor H. Jimenez-Zepeda,1 Joseph Mikhael,2 Andrew Winter,1 Norman Franke,1
Esther Masih-Khan,1 Suzanne Trudel,1 Christine Chen,1 Vishal Kukreti,1 Donna E. Reece1The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the
availability of novel agents to treat progressive multiple myeloma (MM).We retrospectively reviewed all MM pa-
tientswho received a secondASCTas salvage therapy at our center fromMarch 1992 toDecember 2009. Eighty-
oneMMpatients received a secondASCT for relapsedMM. Themedian time to relapse after first transplant was
39months (9.83-100). All patients received reinduction therapy before the secondASCT. Thehigh-dose regimen
givenbefore the secondASCTconsistedofmelphalan (MEL) alone in themajority.Complete response, very good
partial response, and partial responsewere seen in 7.7%, 39.7%, and 50%, respectively, at day 100 post-ASCT; the
median time to relapse after the second ASCT was 19 months. Early deaths occurred in 2.6%. Median
progression-free survival (PFS) based on the time to myeloma relapse after first ASCTwas 9.83 months (relapse
#24 months) and 17.3 months (relapse$24 months) (P\.05). Median overall survival (OS) was 28.47 months
(relapse#24months) and 71.3 months (relapse.24months) (P5.006). Second ASCT is a feasible and safe op-
tion for salvage therapy in MM. The best outcomewas observed in patients whose time to progression was.24
months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years.
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Marrow TransplantationKEY WORDS: Autologous stem cell transplant (ASCT), Salvage therapy, Multiple myeloma (MM), Overall
survival (OS), Progression-free survival (PFS)INTRODUCTION
The use of autologous stem cell transplant (ASCT)
as part of initial therapy represents a standard for
patients with multiple myeloma (MM) younger than
65 years and selected cases older than this age [1-4].
However, virtually all patients eventually progress and
require further antimyeloma therapy. The number of
options for patients with relapsed MM has increased
significantly in recent years. Novel therapies such as
thalidomide, lenalidomide, and bortezomib were first
studied in the setting of relapse/refractory disease
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6/j.bbmt.2011.10.044autologous or reduced-intensity allogeneic, can be con-
sidered for relapsed disease, although the efficacy in the
salvage setting is unclear.The available evidence regard-
ing outcomes after salvage ASCT suggests that the pro-
cedure is safe and reasonably effective [8-11]. Reported
rates of progression-free survival (PFS) after second
salvageASCThave differed and have ranged fromame-
dian of 6.8 months to 4.2 years [10,12,13]. Most studies
have found that time to progression after the first
transplant, or, alternatively, the interval between the
first and second transplants, is predictive of outcomes
after the second transplant. However, many of these
reports contained small numbers of patients with
variable periods of follow-up. In this retrospective
analysis, we identified all MM patients who received
a second ASCT as salvage therapy at Princess Margaret
Hospital and evaluated the factors associated with
a better PFS and overall survival (OS) to better define
the role of this modality in relapsed/refractory disease.PATIENTS AND METHODS
Weretrospectively reviewed themedical records of
all the patients included in the Princess Margaret773
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a second salvage ASCT fromMarch 1992 toDecember
2009 to determine: (1) transplant-related mortality
(TRM), (2) overall response rate at day 100 post-
ASCT, and (3) PFS and OS. From March 1992 to
December 2009, a total of 1141patients received an ini-
tial ASCTat our center. Patients relapsing after the ini-
tial stem cell transplant were considered for a second
ASCT if the first transplant was not associated with
severe regimen-related toxicity, organ function was
adequate, theywere younger than 70 years, or exhibited
a good performance status at relapse, responded to
salvage therapy, and who agreed to a second ASCT.
Patients with tandem transplants were excluded, and
no patient received the salvage transplant as a third au-
tograft in this study. In total, 17 patients received a sec-
ond ASCT before the year of 2004, and only 4 patients
received the salvage transplant before the year of 2000.
Patients
Eighty-one patients with documented symptom-
atic MM who received a second salvage ASCT were
identified in the database of the Princess Margaret
Hospital Myeloma service. Data for this retrospective
study were abstracted from the database and patient
medical records, according to protocols approved by
the University Health Network institutional review
board.
Definitions
A transplant was defined as salvage if the patient
had already received a prior ASCT and underwent
a second ASCT after evidence of disease progression,
regardless of the number of lines of treatment admin-
istered after the first ASCT. Patients who received
a planned tandem ASCT were excluded from this
study. PFS was defined as the time from date of
ASCT to disease progression or death, whereas OS
was defined from the date of ASCT to the date of death
from any cause.
Response Assessment
Definitions of response and progression were used
according to the European Blood and Marrow Trans-
plant modified criteria, and a category of very good
partial response (VGPR) was added [14,15]. Response
was assessed after the last cycle of reinduction
chemotherapy as best response and on day 100 after
the second ASCT in all the cases. Responses were
categorized as complete response (CR) if there was
disappearance of monoclonal protein in the serum
and urine by electrophoresis and immunofixation,
disappearance of any soft tissue plasmacytoma, and
\5% plasma cells in bone marrow as well as
normalization of the free light chain ratio. VGPR was
defined as serum and urine M-component detectableby immunofixation but not by electrophoresis, or 5
90% or greater reduction in the serum M-component
plus urine M-component\100 mg per 24 hours [15].
Responses were categorized as CR if there was disap-
pearance of monoclonal protein in the serum and urine
by electrophoresis and immunofixation, disappearance
of any soft tissue plasmacytoma, and\5% plasma cells
in bone marrow as well as normalization of the free
light chain ratio. VGPRwas defined as serum and urine
M-component detectable by immunofixation but not
by electrophoresis, or 5 90% or greater reduction in
the serum M-component plus urine M-component
\100 mg per 24 hours. All response categories
required 2 consecutive assessments. It is important to
note that the free light chain assay was instituted at
our center in 2004 and therefore was considered as
part of the response assessment when it became avail-
able. All patients underwent serum and urine protein
electrophoresis, serum and urine immunofixation,
and when available, serum-free light chain assays. After
day 100 assessment, patients were seen in the clinic at
least every 2 to 3months or evenmore often as per phy-
sician discretion. PFS was defined as the time from the
second ASCT to disease progression or death [15].
Eligibility for Transplantation
Following the diagnosis of progressive disease,
patients were considered potential candidates for sal-
vage transplantation if the first transplant was not
associated with severe regimen-related toxicity, organ
function was adequate, and sufficient numbers of CD
34-positive cells were available. Early in the PMH ex-
perience, a minimum duration of benefit after the first
transplant was not required. More recently, patients
were preferentially considered for salvage ASCT if
the remission duration following the first procedure
exceeded 2 years. In addition, an Eastern Cooperative
Oncology Group performance status score of 2 or bet-
ter was required to be considered eligible for a second
ASCT. Patients older than 65 years with a good per-
formance status were also eligible for transplantation.
All patients received re-induction therapy before
second ASCT.
Statistical Analyses
The role of the interval between the first ASCT on
PFS and OS was evaluated. The Cox proportional
hazard model was used to perform univariate analyses
of possible prognostic variables for PFS and OS, after
confirming the proportionality of each variable
using time-dependent covariates. To examine which
variables were independently prognostic for PFS and
OS, multivariate Cox analysis was performed using
backward stepwise selection methods. Differences in
continuous variables between groups were compared
using Mann-Whitney or Kruskal-Wallis tests. Survival
Table 1. Clinical Characteristics of Patients with Multiple
Myeloma Who Underwent a Second Autologous Stem Cell
Transplant as Salvage Therapy
Clinical Characteristic (n 5 81) Median Range %
Age (years) 55 30-67
Male 60%
Female 40%
IgG 51.9%
IgA 24.4%
IgM 1.2%
Light chain 17.3%
IgD 1.2%
Nonsecretory 3.7%
Maintenance after ASCT2:
None 66.7%
Thalidomide and prednisone 1.4%
Prednisone 22.2%
IFN 1.4%
Response rate:
Complete response 7.7%
Very good partial response 39.7%
Partial response 50%
Stable disease 1.3%
Progressive disease 1.3%
Early deaths 2.6%
Table 2. Induction Therapy before First and Salvage ASCT in
Patients with Multiple Myeloma Treated at Princess Margaret
Hospital
Clinical Characteristic (n 5 81) %
Induction therapy before first ASCT
Thalidomide and dexamethasone 3.7%
Melphalan and prednisone 6.1%
Dexamethasone 9.6%
VAD 76%
Others 3.7%
Induction therapy before salvage ASCT
Melphalan and prednisone 3.7%
Lenalidomide and dexamethasone 3.7%
DPACE 5%
Vincristine, doxorubicin, and dexamethasone 5%
Bortezomib and dexamethasone 6%
Thalidomide and dexamethasone 17%
Dexamethasone 25%
Cyclophosphamide with either prednisone or dexamethasone 34%
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method and compared using the log-rank test. All
analyses were performed using the SPSS 13.0 software.RESULTS
Patient Characteristics
Between March 1992 and December 2009, 81 pa-
tients received a second ASCT for relapsed MM at our
institution. Clinical characteristics are seen in Table 1.
Median age at first ASCT was 55 years (range: 30-67
years), and 60% were male. Time from diagnosis to
first ASCT was 13 months. The median time to pro-
gression of MM after first transplant was 39 months
(range: 9.83-100 months).
Induction Therapy before the First ASCT
Before the first ASCT, patients received induction
with thalidomide and dexamethasone (3.7%); melpha-
lan and prednisone (6.1%); dexamethasone (9.6%);
vincristine, doxorubicin, and dexamethasone (76%);
and others (3.7%). Median OS from first ASCT was
102 months (confidence interval [CI] 95%, 85.8-
119). At day 100 after first ASCT, response was as-
sessed showing CR in 4.9%, near-CR 2.5%, VGPR
7.4%, partial response (PR) 50.6%, stable disease
11.1%, molecular remission 2.5%, and unknown
21% (Table 2).MedianOSwas not significantly differ-
ent between patients who achieved VGPR/CR after
first ASCT in comparison to those who did not (P 5
.48). Median PFS for patients achieving VGPR/CR
was 2.9 years versus 3.2 years for those who achieved
less than VGPR (P 5 .5).Induction Therapy before Second ASCT
Before the salvage ASCT, 78 patients (96%) re-
ceived steroids, either dexamethasone- or prednisone-
containing regimens. Most of them had received at
least 1 prior therapy (median 5 1). Specific agents/
regimens given included cyclophosphamide and ste-
roids in 28 patients (34%), dexamethasone in 20
(25%), Vincristine, Adriamycin and Dexamethasone
(VAD) in 4 (5%), thalidomide and dexamethasone in
14 (17%), D-PACE in 4 (5%), melphalan and predni-
sone in 3 (3.7%), lenalidomide and dexamethasone in
3 (3.7%), and bortezomib with dexamethasone in
5 (6%) (Table 2). Response assessment before salvage
ASCT showed CR in 0%, VGPR 12.5%, PR 73.8%,
and less than PR in 13.8%. OS tended to be longer
for those patients achieving VGPR (median OS was
not reached for patients achieving VGPR before
salvage ASCT versus 53 months for those who did
not achieve at least VGPR, P 5 .09). On the other
hand, PFS was shorter for patients who did not achieve
at least VGPR than those who did (median PFS
of 16.33 months versus 21.7 months, respectively,
P5 .005).
Stem Cell Collection
The stem cells were mobilized from the peripheral
blood with granulocyte colony-stimulating factor and
cyclophosphamide. Thirty of the 81 required recollec-
tion of cells for the second transplant. The median
length of time to a platelet count $50  109/L and
neutrophil count $0.5  109/L were 11.3 days and
11.6 days, respectively, for the first ASCT and 12.2
days and 13.3 days, respectively, for the second
ASCT. There was a significant difference between
platelet engraftment but not neutrophil engraftment
from first to second ASCT (P5 .022 and .175, respec-
tively). In addition, there was no significant difference
in days to engraftment of neutrophils or platelets from
Figure 1. Progression-free survival for MM patients undergoing a sec-
ond ASCTas salvage therapy according to the length of remission from
the first ASCT.
Figure 2. Overall survival for MM patients undergoing a second ASCT
as salvage therapy according to the length of remission from the first
ASCT.
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the first ASCT (P 5 .853 and .212, respectively).
Furthermore, we confirmed no difference in days to
engraftment of neutrophils and platelets between cells
stored for shorter versus longer periods of time
(\4 years versus .4 years, P 5 .924 and .566).
Conditioning Regimen
Patients were conditioned, infused, and monitored
on an inpatient basis. The majority of patients received
high-dose melphalan, 200 mg per square meter given
intravenously on day 21, and stem cells were infused
on day 0. The high-dose melphalan was reduced to
140 mg per square meter in 2 patients with abnormal
kidney function (creatinine .200 mmol/L). The
high-dose regimen for the first transplant consisted
of melphalan (MEL) 1 total body irradiation (TBI)
in 6, MEL alone in 69, and other combinations in 7
(etoposide/MEL and MEL/TBI). For the second
ASCT, 2 received MEL 1 TBI 6 etoposide, 1 was
given busulfan and cyclophosphamide, and the rest
of the patients received MEL (78). Median CD34
counts were 9.8 106/L and 6.15  106/L for the first
and second ASCT, respectively.
TRM and Morbidity
The all-cause day 100 mortality after second sal-
vage ASCT was 2.6% (N 5 2). Both patients died
because of severe sepsis within 45 days post-ASCT.
One patient developed acute aspiration pneumonia
and coagulase-negative staphylococcal bacteremia as
well as nonspecific enterocolitis with diarrhea, whereas
the second patient developed herpes zoster and acute
pneumonia. Febrile neutropenia was reported in
70%. Eighty percent required either red blood or
platelet transfusions. Patients received supportive
therapy, including bisphosphonates and erythropoie-
tin, as clinically indicated before and after ASCT.
Prophylactic acyclovir was not mandatory, and antith-rombotic agents were also recommended and were
administered at the physician’s discretion. The patient
who died with zoster infection did not receive acyclovir
prophylaxis.
Response Assessment
On day 100 after ASCT, CR, VGPR, and PR
responses were seen in 7.7%, 39.7%, and 50%, respec-
tively. Overall response rate was 97.4% at day 100,
excluding the 2 patients who died before assessment.
One patient experienced progressive disease before
day 100 and was treated with another line of therapy,
and another achieved only stable disease.
Maintenance after Second ASCT
Maintenance therapy was given to 30 patients in an
attempt to increase PFS. Sixteen patients received pred-
nisone, 6 patients thalidomide alone, 1 patient received
thalidomide and prednisone, and 1 more interferon.
PFS and OS were similar for MM patients whether
or not they received maintenance therapy (P 5 .30).
In the univariate analysis, maintenance therapy was
included as a categoric variable showing no difference
for both OS and PFS.
PFS and OS
At a median follow-up of 36 months, 48 patients
(60%) are still alive and 56 (76%) have progressed.
Median (PFS) calculated according to the time to my-
eloma relapse after the first ASCT was 9.83 months
(relapse #24 months), 16.70 months (relapse .24
but \36 months), and 21.17 months (relapse .36
months) (P \ .05). Furthermore, median PFS was
17.30 months (relapse $24 months) versus 9.83
months (relapse #24 months) (P 5 .03) (Figure 1).
Median OS was 28.47 months (relapse #24 months)
and 71.3 months (relapse .24 months) (P 5 .006)
(Figure 2). The use of maintenance therapy did not
Figure 3. Overall survival for MM patients undergoing a second ASCT
as salvage therapy according to the achievement of at least very good
partial response.
Figure 4. Progression-free survival for MM patients undergoing a sec-
ond ASCT as salvage therapy according to the achievement of at least
very good partial response.
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patients who achieved at least VGPR was not yet
reached versus 38.9 months for those who achieved
less than VGPR (P 5 .0001) (Figure 3). Median PFS
for patients who did not achieve at least VGPR was
13.93 months versus 23 months for those achieving
VGPR (P\ .05) (Figure 4).
Univariate and Multivariate Analyses
Prognostic variables before the second ASCTwere
examined for significance in univariate analyses includ-
ing: age, response to initial ASCT, prior therapies,
maintenance, time to relapse after first ASCT
(\24 months versus .24 months), abnormal cytoge-
netics, high-dose regimen, beta-2 microglobulin,
hemoglobin, creatinine, albumin, lactate dehydroge-
nase, and achievement of at least VGPR after reinduc-
tion and second ASCT. Beta-2 microglobulin and
cytogenetics were not informative because of a high
percentage of missing values. The achievement of at
least VGPR and the longer progression-free status
after first ASCT (.24 months) were the most impor-
tant factors predictive of OS (P 5 .007 and .0001,
respectively).DISCUSSION
Despite many advances in the treatment of MM,
a cure has been elusive and patients typically require
sequential regimens to control the disease as long as
possible. A second ASCT has been employed in the
management of recurrent MM by several groups
[2,8-10,12,16-18]. We found that a second ASCT is
a feasible and safe salvage therapy in patients with
relapsed MM, as manifest by a TRM of 2.6%. A
delay in platelet engraftment by 2 days following
the second ASCT has been reported [16]. We did
confirm this finding in our treated patients only
when recollection was required and only in regard to
platelet engraftment (median time for neutrophil andplatelet engraftment was 10 days and 11 days for those
who did not require recollection versus 11 days and
14 days for those who required a second collection)
(P 5 .02 for platelet engraftment). The delay in plate-
let engraftment reported by others could be related to
the lower median CD341 cell dose infused before the
second ASCT, or perhaps a lower quality graft as there
was also a higher median nucleated cell dose. In our
series, the median CD341 cell was 6.15  106/L and
this may explain the absence of delay on platelet en-
graftment in our patients who did not require a second
collection (N 5 51).
A second ASCT in our patients was effective, pro-
viding a median PFS of 16.43 months (CI 13.09-19.78)
and median overall survival of 53 months (CI 41.2-
65.7). These outcomes with a second ASCT compare
favorably with other salvage therapies, but patient
selection and bias likely contribute to these findings,
as patients with aggressive disease and/or poor perfor-
mance status were not offered this therapy [6,19-22].
Although there is a precedent for repeating first-line
therapy in other hematological malignancies, as long
as it was effective for certain minimal period, there
would be reservations about preferentially repeating
ASCT if its use compromised the efficacy of novel
agents used for subsequent relapse. We have also had
the opportunity to assess the effectiveness of the lena-
lidomide and dexamethasone combination in relapsed
myeloma in patients who have never undergone
ASCT, who have received a single ASCT, and who
have been treated with a second salvage ASCT. It is re-
assuring that the duration of therapy with lenalido-
mide plus dexamethasone, and hence efficacy, was
similar in all 3 groups [23].
Interestingly, this study confirms the prognostic
impact of achieving at least VGPR in the context of
a second salvageASCT.This response categorywas in-
troduced by the Intergroupe Francophone Myelome
(IFM), and achievement of at least VGPR was associ-
ated with a significantly better outcome in the IFM
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patients with MM [24]. In our study, the achievement
of at least VGPR after second salvage ASCT was iden-
tified as the most important factor in multivariate anal-
ysis and was associated with a significant prolongation
of PFS and overall survival (P5 .007 and .0001, respec-
tively). Our study is the first to confirm the benefit of
achieving at least VGPR in the setting of ASCT as sal-
vage therapy, and further supports the introduction of
this response criterion, as proposed in the International
Myeloma Working Group uniform criteria [15]. It
should be noted that the presence of cytogenetic ab-
normalities was not assessed in this study because of
missing data in the majority of cases. The number of
prior lines of therapy was previously reported as 1 of
the major factors to predict survival [12]. This is likely
a surrogate marker for the presence of chemoresistant
disease or the persistence of subclinical cumulative tox-
icity from prior therapies but also could reflect an in-
crease of acquired genetic aberrations such as p53
deletion [25].
Our observation that time to progression after the
first ASCT was the most important factor predicting
both PFS and OS is consistent with other previous re-
ports of salvage ASCT [10,16,26]. Other studies have
found that the interval between transplants is
prognostic for OS [13,27] (an interval of .1 year
between the first and the salvage transplant). The
progression-free interval was not found to be clinically
significant in other smaller studies; however, lower
patient numbers and a relatively short follow-up may
have limited the analysis [12]. Despite the limitations
of our study, specifically its retrospective nature, and in-
complete data on prognostic markers such as genetic
abnormalities, it represents the largest description of
long-term outcomes for patients who undergo a second
ASCT as salvage therapy. Recently, a multivariate anal-
ysis on 55 patients undergoing a salvage transplant sug-
gests that a duration of remission of more than
12months after the first transplant is a predictive factor
for both OS and PFS [28]. Based on these previous re-
ports and our data, we can conclude that a second
ASCT is feasible and safe salvage therapy exhibiting
the best benefit in patients whose time to progression
lasts longer after the first ASCT. These patients had
a subsequent remission lasting over 1 year, with a signif-
icant improvement in overall survival and PFS. It is rea-
sonable, therefore, to consider a second ASCT,
particularly if the time to progression is longer after
the first transplant; whether 1 or 2 years remission after
first transplant should be considered the cutoff for a sal-
vage transplant remains to be elucidated.AUTHORSHIP STATEMENT
Victor H. Jimenez-Zepeda, Joseph Mikhael, An-
drew Winter, Norman Franke, Esther Masih-Khan,Suzanne Trudel, Donna E. Reece, Christine Chen,
and Vishal Kukreti designed research, analyzed data,
and wrote the paper. Each of the authors reviewed
and approved the manuscript for submission. All
authors have reviewed the manuscript, agree with its
contents, and consent to its submission to BBMT.ACKNOWLEDGMENTS
Financial disclosure: The authors declare no com-
peting financial interests. Jimenez-Zepeda V is a re-
cipient of the MMRF Research fellow award.REFERENCES
1. Bjorkstrand B, Gahrton G. High-dose treatment with autolo-
gous stem cell transplantation in multiple myeloma: past, pres-
ent, and future. Semin Hematol. 2007;44:227-233.
2. Harousseau JL. Role of stem cell transplantation.Hematol Oncol
Clin North Am. 2007;21:1157-1174.
3. Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R,
Kochupillai V. High-dose chemotherapy with autologous stem
cell transplantation formultiplemyeloma: what predicts the out-
come? Experience from a developing country. Bone Marrow
Transplant. 2009;43:481-489.
4. Jantunen E, et al. High-dose melphalan (200 mg/m2) supported
by autologous stem cell transplantation is safe and effective in
elderly (.or 5 65 years) myeloma patients: comparison with
younger patients treated on the same protocol. Bone Marrow
Transplant. 2006;37:917-922.
5. Engelhardt M, Kleber M, Udi J, et al. Consensus statement
from European experts on the diagnosis, management, and
treatment of multiple myeloma: from standard therapy to novel
approaches. Leuk Lymphoma. 2010;51:1424-1443.
6. Rajkumar SV.Multiplemyeloma: 2011update ondiagnosis, risk-
stratification, and management. Am J Hematol. 2011;86:57-65.
7. ReeceDE. Recent trends in themanagement of newly diagnosed
multiple myeloma. Curr Opin Hematol. 2009;16:306-312.
8. Alvares CL, Davies FE, Horton C, Patel G, Powles R,
Morgan GJ. The role of second autografts in the management
of myeloma at first relapse. Haematologica. 2006;91:141-142.
9. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or al-
logeneic transplantation for multiple myeloma refractory to or
relapsing after a first-line autograft? Bone Marrow Transplant.
1998;21:887-892.
10. Mikhael JR, Zadeh S, Samiee S. Second autologous stem cell
transplant (ASCT) as salvage therapy in patients with relapsed
multiple myeloma: improve outcomes in patients with longer
disease free interval after first ASCT. Blood. 2007;110.
11. TricotG, JagannathS,VesoleDH,Crowley J,BarlogieB.Relapse
of multiple myeloma after autologous transplantation: survival
after salvage therapy. Bone Marrow Transplant. 1995;16:7-11.
12. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe
and effective salvage therapy for relapsed multiple myeloma.
Bone Marrow Transplant. 2009;43:417-422.
13. Qazilbash MH, Sallba R, De Lima M, et al. Second autologous
stem cell transplant or allogeneic transplantation after failure of
first autograft in patients with multiple myeloma. Cancer J.
2006;106.
14. Blade J, SamsonD, Reece D, et al. Criteria for evaluating disease
response and progression in patients with multiple myeloma
treated by high-dose therapy and haemopoietic stem cell trans-
plantation. Myeloma Subcommittee of the EBMT. European
Group for Blood and Marrow Transplant. Br J Haematol.
1998;102:1115-1123.
15. Durie BG, Harousseau JL, Miguel JS, et al. International uni-
form response criteria for multiple myeloma. Leukemia. 2006;
20:1467-1473.
Biol Blood Marrow Transplant 18:773-779, 2012 779Second ASCTas Salvage Therapy in Myeloma16. Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second au-
tologous peripheral blood stem cell transplant in patients with
relapsed or recurrent multiple myeloma. Leuk Lymphoma.
2009;50:1442-1447.
17. HongJY,ChoiMK,KimDH.Feasibilityof secondhematopoietic
stem cell transplantation using reduced-intensityconditioning
with fludarabine and melphalan after a failed autologous hemato-
poietic stem cell transplantation.Transplant Proc. 2010Nov;42(9):
3723-3728.
18. Krejci M, Adam Z, Buchler T, et al. Salvage treatment with up-
front melphalan 100 mg/m(2) and consolidation with novel
drugs for fulminant progression ofmultiplemyeloma.AnnHem-
atol. 2010;89(5):483-487.
19. BensingerW. Stem-cell transplantation formultiplemyeloma in
the era of novel drugs. J Clin Oncol. 2008;26:480-492.
20. Kyle RA, Rajkumar SV. Treatment of multiplemyeloma: a com-
prehensive review. Clin Lymphoma Myeloma. 2009;9:278-288.
21. Rajkumar SV, PalumboA.Management of newly diagnosedmy-
eloma. Hematol Oncol Clin North Am. 2007;21:1141-1156, ix-x.
22. Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or
transplantation in the era of new drugs. Eur J Haematol. 2010
May;84(5):379-390.23. Reece D, Gill W, Masih-Khan E, et al. Efficacy of lenalidomide
therapy in patients with relapsed/refractory multiple myeloma:
influence of number and timing of prior ASCT(s).Haematologica.
2011;(Suppl 1).
24. Harousseau JL. Integrating novel therapies in the transplant
paradigm. Cancer J. 2009;15:479-484.
25. SoledadMolnar VJJZ, VanWier S, Braggio E, et al. Loss of p53
is a marker of progression in plasma cell neoplasias and is
a negative prognostic factor in relapsed disease. Blood. 2008;
112:1663.
26. Barlogie B, Hall R, Zander A, Dickie K, Alexania R. High-dose
melphalan with autologous bone marrow transplantation for
multiple myeloma. Blood. 1986;67:1298-1301.
27. Cook G, Liakopoulou E, Pearce R, et al. Factors influencing the
outcome of a second autologous stem cell transplant (ASCT) in
relapsed multiple myeloma: a study from the British Society of
Blood and Marrow Transplantation Registry. Biol Blood Marrow
Transplant. 2011;17:1638-1645.
28. Fenk R, Liese V, Neubauer F, et al. Predictive factors for suc-
cessful salvage high-dosetherapy in patients with multiple mye-
loma relapsing after autologous blood stem cell transplantation.
Leuk Lymphoma. 2011 Aug;52(8):1455-1462.
